Nirmala Raghavan
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Drug Transport and Resistance Mechanisms, Analytical Chemistry and Chromatography, Eicosanoids and Hypertension Pharmacology, Inflammatory mediators and NSAID effects
Most-Cited Works
- → Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans(2008)601 cited
- → In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies(2009)251 cited
- → Comparative Metabolism of 14C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans(2009)104 cited
- → Sulfation of O-Demethyl Apixaban: Enzyme Identification and Species Comparison(2009)58 cited
- → Reductive Isoxazole Ring Opening of the Anticoagulant Razaxaban Is the Major Metabolic Clearance Pathway in Rats and Dogs(2007)56 cited
- → Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design(2021)42 cited
- → LC-MS/MS-Based Approach for Obtaining Exposure Estimates of Metabolites in Early Clinical Trials Using Radioactive Metabolites as Reference Standards(2007)39 cited
- → Comparative Metabolism of Radiolabeled Muraglitazar in Animals and Humans by Quantitative and Qualitative Metabolite Profiling(2006)31 cited
- → Cytochrome P450 11A1 Bioactivation of a Kinase Inhibitor in Rats: Use of Radioprofiling, Modulation of Metabolism, and Adrenocortical Cell Lines to Evaluate Adrenal Toxicity(2012)27 cited
- → Plasma Stability-Dependent Circulation of Acyl Glucuronide Metabolites in Humans: How Circulating Metabolite Profiles of Muraglitazar and Peliglitazar Can Lead to Misleading Risk Assessment(2010)24 cited